Verve Therapeutics Inc. (VERV)
Company Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.
Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Dr. Kiran Musunuru M.D., M.P.H., Ph.D. |
Contact Details
Address: 500 Technology Square Cambridge, Massachusetts United States | |
| Website | https://www.vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer |
| Issi Rozen M.B.A. | Co-Founder & Strategic Advisor |
| Jennifer Robinson | Senior Vice President of Investor Relations & Corporate Communications |
| Joan Nickerson M.B.A. | Chief Administrative Officer |
| Kaitlin Duffy | Executive Director of Human Resources |
| Yasser M. El-Gamal J.D. | Senior Vice President of Legal Affairs & Chief Intellectual Property Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | SCHEDULE 13G | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |
| Apr 03, 2025 | 4 | Filing |